CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
CCTG welcomes new Patient Representative Sally Nystrom who will be supporting the CCTG Melanoma Committee
The 2024 EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics was held last week in Barcelona and CCTG was there with two IND poster presentations. The ENA symposium is a leading event for drug development and translational research. It focuses on preclinical, and phase I studies and provides a platform for scientific discussions on the latest advancements in targets and therapeutics.
OVC2 primary publication: Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
The myeloMATCH North American platform study is now open in Canada and comprises a series of clinical trials to treat patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
MAC30 has recently opened in Canada and will compare two commonly used treatment choices for premenopausal women with ER-positive/HER2-negative breast cancer and a low to intermediate risk of recurrence. Researchers are testing the addition of chemotherapy to ovarian function suppression plus hormonal therapy versus ovarian function suppression plus hormonal therapy alone. Both these approaches are used across North America, and it is not clear as to whether chemotherapy is needed in this population.
